Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer
Juliane Baumgart(Örebro University), Inger Sundström Poromaa(Uppsala University), Henrik Lindman(Uppsala University), Anneli Stavreus‐Evers(Uppsala University), Theodora Kunovac Kallak(Uppsala University), Kerstin Nilsson(Örebro University), Kenneth Villman(Örebro University Hospital), Kristiina Kask(Uppsala University)
Cited by 91
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260